Smith MR - Search Results

1

Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial.

Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford D, Manarite J, Muslin D, Farrington T, Tombal B. Smith MR, et al. Future Oncol. 2022 Jul;18(21):2585-2597. doi: 10.2217/fon-2022-0433. Epub 2022 Jun 3. Future Oncol. 2022. PMID: 35656777 Free article. Review.

2

Depression in men receiving androgen deprivation therapy for prostate cancer: a pilot study.

Pirl WF, Siegel GI, Goode MJ, Smith MR. Pirl WF, et al. Among authors: smith mr. Psychooncology. 2002 Nov-Dec;11(6):518-23. doi: 10.1002/pon.592. Psychooncology. 2002. PMID: 12476433

3

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.

Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Smith MR, et al. J Urol. 2003 Jun;169(6):2008-12. doi: 10.1097/01.ju.0000063820.94994.95. J Urol. 2003. PMID: 12771706 Clinical Trial.

4

Prostate cancer (metastatic).

Michaelson MD, Smith MR, Talcott JA. Michaelson MD, et al. Among authors: smith mr. Clin Evid. 2003 Dec;(10):1012-22. Clin Evid. 2003. PMID: 15555135 Review. No abstract available.

5

Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer.

Smith MR, Kabbinavar F, Saad F, Hussain A, Gittelman MC, Bilhartz DL, Wynne C, Murray R, Zinner NR, Schulman C, Linnartz R, Zheng M, Goessl C, Hei YJ, Small EJ, Cook R, Higano CS. Smith MR, et al. J Clin Oncol. 2005 May 1;23(13):2918-25. doi: 10.1200/JCO.2005.01.529. J Clin Oncol. 2005. PMID: 15860850 Clinical Trial.

6

Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer.

Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, Saad F, Smith MR. Cook RJ, et al. Among authors: smith mr. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3361-7. doi: 10.1158/1078-0432.CCR-06-0269. Clin Cancer Res. 2006. PMID: 16740758 Clinical Trial.

7

Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer.

Smith MR, Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, Saad F. Smith MR, et al. Urology. 2007 Aug;70(2):315-9. doi: 10.1016/j.urology.2007.03.071. Urology. 2007. PMID: 17826496 Free PMC article. Clinical Trial.

8

Management of complications of prostate cancer treatment.

Michaelson MD, Cotter SE, Gargollo PC, Zietman AL, Dahl DM, Smith MR. Michaelson MD, et al. Among authors: smith mr. CA Cancer J Clin. 2008 Jul-Aug;58(4):196-213. doi: 10.3322/CA.2008.0002. Epub 2008 May 23. CA Cancer J Clin. 2008. PMID: 18502900 Free PMC article. Review.

9

Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks.

Isbarn H, Boccon-Gibod L, Carroll PR, Montorsi F, Schulman C, Smith MR, Sternberg CN, Studer UE. Isbarn H, et al. Among authors: smith mr. Eur Urol. 2009 Jan;55(1):62-75. doi: 10.1016/j.eururo.2008.10.008. Epub 2008 Oct 14. Eur Urol. 2009. PMID: 18945543 Free PMC article. Review.

10

Denosumab in men receiving androgen-deprivation therapy for prostate cancer.

Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C; Denosumab HALT Prostate Cancer Study Group. Smith MR, et al. N Engl J Med. 2009 Aug 20;361(8):745-55. doi: 10.1056/NEJMoa0809003. Epub 2009 Aug 11. N Engl J Med. 2009. PMID: 19671656 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,177 results

Search Page

Filters